This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EW Stock Climbs on Q2 Earnings & Revenue Beat, Margins Down
by Zacks Equity Research
Edwards Lifesciences posts a second-quarter 2025 earnings and revenue beat, with strong growth in TAVR and TMTT segments despite margin pressure.
Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?
by Zacks Equity Research
RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.
WST Stock Rises on Q2 Earnings Beat, EPS View Up on Tariff & FX Benefit
by Zacks Equity Research
West Pharmaceutical's second-quarter top line continues to benefit from revenue growth in its Proprietary Products segment.
Will DXCM Q2 Earnings Reflect U.S. Coverage Expansion & Stelo Impact?
by Zacks Equity Research
DexCom Q2 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Can Robust Invisalign Momentum Drive Align Technology's Q2 Earnings?
by Zacks Equity Research
ALGN is likely to have delivered robust Q2 2025 performance as Invisalign traction and iTero upgrades gained steam across global markets.
Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up
by Zacks Equity Research
BSX beats Q2 estimates, raises full-year outlook as Cardiovascular sales surge and global revenues climb 22.8%.
Universal Health to Report Q2 Earnings: What Do the Key Estimates Say?
by Zacks Equity Research
UHS' Q2 results are likely to reflect gains from hospital and behavioral health services. However, rising costs may cloud earnings upside.
ISRG Stock Gains on Q2 Earnings & Sales Beat, Gross Margin Contracts
by Zacks Equity Research
Intuitive Surgical's second-quarter results reflect a healthy demand for procedures on higher system utilization. However, tariffs lead to a decline in the gross margin outlook.
WST Q2 Earnings Preview: Will the Stock's Segmental Edge Hold Up?
by Zacks Equity Research
West Pharmaceutical targets steady Q2 growth as high-value GLP-1 and SmartDose demand drives segment momentum.
Quest Diagnostics Beats Q2 Earnings & Revenue Estimates, Stock Rises
by Zacks Equity Research
DGX tops Q2 estimates with 15.2% revenue growth and a strong EPS beat, lifting the stock 3.2% in pre-market trading.
Robust TMTT Growth to Drive Edwards Lifesciences' Q2 Earnings
by Zacks Equity Research
EW's Q2 earnings report is likely to benefit from soaring TMTT sales, with the segment expected to jump over 57% year over year.
HCA Healthcare to Report Q2 Earnings: Key Estimates to Note
by Zacks Equity Research
The Zacks Consensus Estimate for HCA's Q2 EPS and revenues suggests a year-over-year upside despite higher costs and surgery volume pressure.
ECL Unveils ReadyDose Cleaning Program for Southeast Asian Restaurants
by Zacks Equity Research
Ecolab rolls out ReadyDose, a tablet-based cleaning solution to help Southeast Asian restaurants cut waste and boost hygiene.
Labcorp Q2 Earnings Preview: Diagnostics Strength in Focus
by Zacks Equity Research
LH is likely to report Q2 growth with diagnostics momentum, key acquisitions, and new biomarker tests bolstering revenue gains.
DGX Q2 Earnings Preview: Will Advanced Diagnostics Lead Performance?
by Zacks Equity Research
Quest Diagnostics' Q2 results may get a lift from Advanced Diagnostics, new health plan deals and recent acquisitions.
Molina to Report Q2 Earnings: Healthy Revenues, Weak Pulse on Earnings
by Zacks Equity Research
MOH's Q2 revenues are set to rise nearly 10%, but rising costs cloud its profit outlook.
Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.
TMO to Report Q2 Earnings: Analytical Instruments Segment in Focus
by Zacks Equity Research
Thermo Fisher eyes second-quarter 2025 growth with new tech launches in Analytical Instruments and Life-Science Solutions segments.
Should You Add Edwards Lifesciences Stock to Your Portfolio Now?
by Zacks Equity Research
EW gains traction with surgical tech and TAVR growth, but macro pressures and FX headwinds weigh on margins.
ISRG's Vessel Sealer Curved for da Vinci Systems Gets FDA Approval
by Zacks Equity Research
Intuitive Surgical wins FDA nod for its Vessel Sealer Curved, boosting the da Vinci system's precision and multifunctional capabilities.
ANGO Stock Down Despite Q4 Earnings Beat, Gross Margin Declines
by Zacks Equity Research
AngioDynamics beats fourth-quarter fiscal 2025 estimates with strong Med Tech growth amid margin declines and a wider fiscal 2026 loss outlook.
Reasons to Add DENTSPLY SIRONA Stock to Your Portfolio Now
by Zacks Equity Research
XRAY gains traction with digital implants, R&D strength, and Q1 margin growth despite softness in Europe.
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
Expanding product portfolio and high prospects for POC raise optimism for INGN stock.
GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?
by Zacks Equity Research
Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.